Valeant Pharmaceuticals may get some help in buying Cephalon from one of the company's investors.  Read the full story

Cephalon is once again on the acquisition trail Read the full story

Cephalon, Inc. has announced it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Read the full story

Celator Pharmaceuticals has announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. Read the full story

Infectious disease deals were the dominant headline value deal makers in Q4, 2010. This follows metabolism deals as the dominant therapy area in Q2 and Q3 of 2010. In total there were 65 deals announced in infectious disease out of a total of 212. This translates into to a Current Agreements scorecard headline value of $4.96 billion for infectious disease deals. Read the full story

Cephalon, the largest biotechnology company in the regenerative medicine sector, have licensed Mesenchymal Precursor Stem Cell (MPC) therapeutics from Mesoblast for over $2 billion. Read the full story

Cephalon, Inc. and Mesoblast Limited have announced they have entered into a strategic alliance to develop and commercialise novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems. Read the full story

Cephalon has once again demonstrated tremendous business acumen and expanded its range of pharmaceutical products and services within the developed and emerging markets with the acquisition of Mepha for $615.4 million. Read the full story

Cephalon will buy Mepha AG, the Swiss generic drugmaker owned by Germany's Merckle family, for about $590 million (622.5 million Swiss francs) to diversify its product line and expand internationally.

Cephalon will pay BDC an upfront payment of $30 million and, assuming exercise of the option, an additional payment on the closing of the acquisition. BDC stockholders could also receive additional future payments related to regulatory and sales milestones. The option agreement is subject to customary closing conditions including the receipt of necessary BDC stockholder approvals.